Recursion and Tempus AI Expand Partnership: $12M TxFM License and Revised Data Terms
RXRX sits 41% above its 52-week low of $2.77 on elevated volume (2.3× avg).
Summary
Recursion granted Tempus AI a 2-year oncology license to its TxFM RNA model for $12M in fees, and amended their master data agreement to lower annual fees to $14M while extending the term and removing the termination-for-convenience right.
Key Events · M&A and Partnerships · RXRX
-
TxFM License Agreement with Tempus
Recursion granted Tempus a non-exclusive, worldwide, 2-year license to its TxFM RNA foundation model for oncology use in exchange for a $12M non-refundable fee, paid in two $6M installments — the first due upon execution.
-
Master Agreement Amendment
The Tempus Master Agreement term was extended from 5 to 6 years, the termination-for-convenience right was eliminated, and annual license fees were revised to $14M for years 3, 4, and 5 (at least $4M cash each year), down from $42M.
-
Immediate Cash Inflow
The first $6M TxFM installment is due upon execution, providing near-term non-dilutive cash against Recursion's $546M cash balance and $131M quarterly net loss.
-
Data Access Reduced
The Amendment decreases the aggregate total of unique de-identified data records Recursion may access during the term, while Tempus will provide access to de-identified pathology records with linked clinical data under the TxFM agreement.
Analysis · RXRX · Life Sciences
Recursion has restructured its data-access relationship with Tempus AI and simultaneously monetized its proprietary RNA foundation model. The TxFM License Agreement brings in $12 million in non-refundable fees — $6 million due immediately — which is meaningful against a $546 million cash balance and a quarterly net loss of $131 million. The Amendment to the Master Agreement reduces future annual license fees from $42 million to $14 million and extends the term, but eliminates Recursion's right to terminate for convenience, locking in a longer commitment. This is a strategic pivot: Recursion is trading some data-access flexibility for near-term cash and a validation of its AI model by a major oncology data player.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1609 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RXRX was trading at $3.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $2.77 to $7.18. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.